Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Septerna, Inc.NASDAQ: SEPN
Other Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Other current liabilities falls 57.2% from a year ago
Other current liabilities stood at $26.4M at the end of Q3 FY2026, down 57.2% from a year earlier and up 123.8% from the prior quarter. Over 3 fiscal years it compounded at +51.2% a year.
Context
- Other current liabilities amounted to 4.3% of total assets at the end of Q3 FY2026, down 5.9 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -57.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6.07M USD
- Year-over-year change
- +44.4%
- 3-year CAGR
- +51.2%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.07M | +44.4% |
| FY2024 | 2024-12-31 | 4.21M | +38.4% |
| FY2023 | 2023-12-31 | 3.04M | +73.1% |
| FY2022 | 2022-12-31 | 1.76M | — |
Other Current Liabilities vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 other current liabilities of $26.4M is the 2nd highest of the 7 companies compared; the peer median is $109.5K.
- Its year-over-year change of -57.2% is the 3rd highest of 5, against a peer median of -69.5%.
- Other current liabilities amounts to 4.3% of total assets for SEPN, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. | Jun 2026 | $82.6M | — | — | 6.8% |
SEPNSepterna, Inc. | Sep 2026 | $26.4M | -57.2% | +51.2% | 4.3% |
| Mar 2026 | $5.42M | -25.5% | +13.2% | 1.3% | |
| Mar 2026 | $159K | -39.1% | -35.7% | 0.3% | |
| Mar 2026 | $60K | — | +40.1% | 0.1% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $0 | -100.0% | +56.2% | 0.0% |
| Jun 2026 | $0 | -100.0% | +52.0% | 0.0% | |
| Peer median (excluding SEPN) | $109.5K | -69.5% | +40.1% | 0.2% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.